Moderna Co-Founder Calls Omicron a Major Threat

The transcript discusses the Omicron variant's global spread and Moderna's response plan, including vaccine efficacy and regulatory considerations. It highlights the importance of antibody levels in determining vaccine effectiveness and speculates on the future of COVID-19 vaccinations, suggesting a possible need for seasonal boosters.

What is the significance of measuring neutralizing antibody levels in the context of new variants?

How does the speaker view the future of COVID-19 vaccinations in relation to seasonal flu shots?

What challenges does the speaker foresee in transitioning from a pandemic to an endemic state?